Literature DB >> 25574911

Markers to differentiate between Kaposi's sarcoma and tuberculous pleural effusions in HIV-positive patients.

M Coleman1, L J Finney2, D Komrower3, A Chitani2, J Bates4, G A Chipungu5, E Corbett6, T J Allain3.   

Abstract

BACKGROUND: Kaposi's sarcoma (KS) and tuberculosis (TB) commonly cause pleural effusions in high human immunodeficiency virus (HIV) burden resource-limited countries. Differentiating between them is challenging, as pleural biopsy and TB culture are rarely available.
OBJECTIVES: To identify markers to differentiate between TB effusions and KS effusions in HIV-positive patients, and to compare liquid culture and Xpert MTB/RIF in pleural fluid.
METHODS: Fifty HIV-positive patients with pleural effusions recruited in Malawi underwent pleural ultrasound and aspiration. Fluid visual inspection, cell count, bacterial culture, glucose/protein, solid and liquid TB culture and Xpert were performed.
RESULTS: The mean age of the patients was 32 years; 30/50 (60%) were male and 29 (58%) had cutaneous/oral KS. Thirteen (26%) pleural fluid samples were liquid culture-positive for TB, while 9/13 (69%) were Xpert-positive. Three (10.3%) KS patients had culture-positive TB effusions; 17 (58.6%) had KS effusions. The relative risk of TB in KS patients increased with limited KS, loculated fluid and low glucose. Eleven (52.3%) non-KS patients had culture-positive TB effusions associated with male sex, straw-coloured fluid and fibrin stranding on ultrasound.
CONCLUSIONS: KS patients were most likely to have KS effusion, but TB should be considered. Most non-KS patients had TB, supporting the use of World Health Organization guidelines. Xpert identified two thirds of liquid culture-positive results.

Entities:  

Mesh:

Year:  2015        PMID: 25574911     DOI: 10.5588/ijtld.14.0289

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

1.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

2.  Xpert MTB/RIF Ultra versus Xpert MTB/RIF for diagnosis of tuberculous pleural effusion: A systematic review and comparative meta-analysis.

Authors:  Ashutosh Nath Aggarwal; Ritesh Agarwal; Sahajal Dhooria; Kuruswamy Thurai Prasad; Inderpaul Singh Sehgal; Valliappan Muthu
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

Review 3.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

Review 4.  Diagnostic Performance of Xpert MTB/RIF in Tuberculous Pleural Effusion: Systematic Review and Meta-analysis.

Authors:  Inderpaul Singh Sehgal; Sahajal Dhooria; Ashutosh Nath Aggarwal; Digambar Behera; Ritesh Agarwal
Journal:  J Clin Microbiol       Date:  2016-01-27       Impact factor: 5.948

5.  Is Xpert MTB/RIF appropriate for diagnosing tuberculous pleurisy with pleural fluid samples? A systematic review.

Authors:  Zhen-Yu Huo; Li Peng
Journal:  BMC Infect Dis       Date:  2018-06-25       Impact factor: 3.090

6.  Accuracy of Xpert MTB/RIF assay for the diagnosis of tuberculous pleural effusion.

Authors:  Yi-Ran Qiu; Yu-Yan Chen; Xin-Ran Wu; Ya-Ping Li; Xun-Jie Cao; Zi-Yuan Yu; Min Lin; Qiu-Yin Li; Ji-Chun Chen; Xin Yin; Shu-Chang Weng; Xu-Guang Guo
Journal:  J Clin Lab Anal       Date:  2021-12-17       Impact factor: 2.352

7.  GeneXpert technology. A breakthrough for the diagnosis of tuberculous pericarditis and pleuritis in less than 2 hours.

Authors:  Muhammad Saeed; Mobeen Ahmad; Shagufta Iram; Saba Riaz; Mehwish Akhtar; Maleeha Aslam
Journal:  Saudi Med J       Date:  2017-07       Impact factor: 1.484

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.